期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量硼替佐米联合地塞米松治疗复发难治性多发性骨髓瘤的疗效 被引量：4

原文传递
导出
摘要 多发性骨髓瘤是一种常见血液系统恶性肿瘤，目前被认为是一种不可治愈的疾病。自2003年一种新的蛋白酶体抑制剂——硼替佐米应用于多发性骨髓瘤患者以来，其治疗有效率、完全缓解率显著提高。但标准剂量硼替佐米（1．3mg／m^2）联合化疗的毒性反应，尤其周围神经病变较常见，严重者影响患者生活。我们采用小剂量硼替佐米联合地塞米松治疗8例难治性多发性骨髓瘤，并观察疗效及不良反应。
作者 李菁媛 谢红 冉启杰 周敏 王军 张新华
机构地区 广州军区武汉总医院血液科
出处 《临床内科杂志》 CAS 2011年第3期201-202,共2页 Journal of Clinical Internal Medicine
关键词 多发性骨髓瘤 复发难治性 硼替佐米 地塞米松
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed, multiple myeloma : final time to event results from the APEX trial. Blood ,2007,110:3557-3560.
  • 2Hideshima T, Richardson P, Chanhan D, et al The proteasome inhibitor PS-341 inhibits growth, inducesapoptosis, and overcome drug resistance in human multiple mielome cell. Cancer Res ,2001,61:3071-3076.
  • 3Jaqannath S,Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol,2005,129:776-783.
  • 4Randomized phase Ⅲ study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : combination therapy improves time to progression. J Clin Oncol,2007,25:3892-3901.
  • 5丛燕,曾晓颖,赵沄,沙颖豪.小剂量硼替佐米联合化疗治疗4例多发性骨髓瘤的疗效[J].中国临床药学杂志,2009,18(3):143-146. 被引量：1
  • 6Palumbo A, Ambrosini MT, Benevolo G, et al Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007,109:2767-2772.

二级参考文献11

  • 1Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloraa: upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial[J]. Blood, 1998,92(9):3131.
  • 2Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial[J] .Lancet,2006,367(9513) :825.
  • 3Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone(Rev/Dex) for newly diagnosed myeloma[J]. Blood,2005,106(13) :4050.
  • 4Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med,2003, 348(26) :2609.
  • 5Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of borteromib in relapsed or refractory myeloma[ J ]. Br J Haematol, 2004,127(2) : 165.
  • 6Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents[J]. Cancer Res, 1999,59(11):2615.
  • 7Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed, multiple myeloma: final time-to-event results from the APEX trial[J]. Blood,2007,110(10) :3557.
  • 8San Miguel JF, Schlag R, Khuageva NE,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J]. N Engl J Med,2008,359(9) :906.
  • 9Pineda-Roman M, Zangari M, Van Rhe F,et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone ib highly effective in advanced and refractory multiple myeloma[ J ]. Leukemia, 2008,22 (7): 1419.
  • 10Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [ J ]. Br J Haematol, 2007,138(3):330.

同被引文献49

  • 1武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235.
  • 2吴晓雄,于力,黄文荣,赵瑜,王全顺,薄剑,李菲,高春记.硼替佐米治疗难治/复发性多发性骨髓瘤的疗效观察[J].临床血液学杂志,2007,20(5):268-269. 被引量：14
  • 3Blade J,Samson D, Reeee D, el al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietie stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J]. Br J Haematol, 1998, 102(5) :1115-1123.
  • 4Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma [ J ]. Oral 0ncol,2012,48(6) :554-559.
  • 5Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma:final time-to-event results of the APEX trial [ J ]. Blood,2007,110 (10) :3557-3560.
  • 6Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with is highly effective in advanced and refractory multiple myeloma [J]. Leukemia,2008,22(7) : 1419-1427.
  • 7San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J]. N Engl J Med,2008,359(9) :906-917.
  • 8Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy [J]. J Clin Oncol,2009,27(21 ) :3518-3525.
  • 9Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [ J ]. N Engl J Med, 1999,341 (21) :1565-1571.
  • 10Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trims of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma [ J ]. Br J Haematol,2006,132 (5) : 584-593.

引证文献4

二级引证文献24

临床内科杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部